Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Zogenix, Inc.
Following accelerated approval of Biogen’s Alzheimer’s drug aducanumab in the US, we look back at 10 of the FDA’s most controversial drug approval decisions, from Addyi to Zohydro.
With action imminent on Biogen’s Alzheimer’s drug aducanumab, the Pink Sheet looks back at 10 of FDA’s most controversial drug approval decisions, from Addyi to Zohydro.
A look at drugs the agency approved despite an advisory committee vote not to do so and how they compare to Biogen’s Alzheimer’s disease drug aducanumab.
Probiotics specialist BioGaia will draw on the experience of its new private equity investor EQT as it looks to expand through acquisitions and increased digitization.
- Other Names / Subsidiaries
- Brabant Pharma, Modis Therapeutics, Inc. Zogenix International, Ltd. Zogenix Europe Limited